GH1 and COVID-19: In our case, the reduction in, and persistence of decreased levels of, GH and IGF-1 could result in a phenotype similar to the one previously mentioned, suggesting that COVID-19 affects the GH/IGF-1 system in a manner akin to ageing, in addition to likely affecting the hypothalamic–pituitary–adrenal (HPA) axis.